α-eleostearic acid inhibits growth and induces apoptosis in breast cancer cells via HER2/HER3 signaling

Zhuo,Ren-Jie; Wang,Feng; Zhang,Xiao-Hong; Zhang,Jin‑Jie; Xu,Jin; Dong,Wei; Zou,Zu-Quan

doi:10.3892/mmr.2014.1892

α-eleostearic acid inhibits growth and induces apoptosis in breast cancer cells via HER2/HER3 signaling

Authors:
- Ren-Jie Zhuo
- Feng Wang
- Xiao-Hong Zhang
- Jin‑Jie Zhang
- Jin Xu
- Wei Dong
- Zu-Quan Zou
View Affiliations

Affiliations: Medical School, Ningbo University, Ningbo, Zhejiang 315211, P.R. China, Clinical Laboratory, Lihuili Hospital, Ningbo, P.R. China, Maritime Faculty, Ningbo University, Ningbo, Zhejiang 315211, P.R. China
Published online on: January 13, 2014 https://doi.org/10.3892/mmr.2014.1892
Pages: 993-998

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

α-eleostearic acid (α-ESA) has been shown to possess antitumor activity in cancer cells. However, the underlying mechanism(s) remain largely unknown. The present study was designed to investigate the antitumor effect of α-ESA in breast cancer cells showing different expression levels of the human epidermal growth factor receptor 2 (HER2). α-ESA inhibited cell growth and induced apoptosis in the SKBR3 and T47D breast cancer cell lines. The mechanism by which cell growth was inhibited involved G0/G1 and G2/M cell cycle phase arrest. The MTT assay showed that SKBR3 cells are more sensitive to α-ESA compared to T47D cells. Western blot analysis revealed that α-ESA treatment not only reduced HER2/HER3 protein expression, but also increased the level of phosphorylated phosphatase and tensin homolog protein (PTEN), which led to decreased levels of phosphorylated Akt. Inactive Akt further reduced phosphorylation of glycogen synthase kinase-3β (GSK-3β) and B-cell lymphoma 2 (Bcl-2)‑associated death promoter (BAD) proteins. Furthermore, the level of the anti-apoptotic protein Bcl-2 was found to be reduced following α-ESA treatment. Notably, nuclear factor κB (NF-κB) was activated by α-ESA treatment. Data of the present study showed that the antitumor activity of α-ESA is at least partly mediated by reduction of the HER2/HER3 heterodimer protein level, activation of the Akt/BAD/Bcl-2 apoptotic pathway and inhibition of the Akt/GSK-3β survival pathway in the two breast cancer cell lines investigated in this study. Therefore, α-ESA may be considered a beneficial dietary factor for the prevention and treatment of invasive breast cancer in cells overexpressing HER2.

View Figures

View References

1	Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, et al: Molecular portraits of human breast tumours. Nature. 406:747–752. 2000. View Article : Google Scholar : PubMed/NCBI
2	Yu D and Hung MC: Role of erbB2 in breast cancer chemosensitivity. Bioessays. 22:673–680. 2000. View Article : Google Scholar : PubMed/NCBI
3	Hynes NE and Lane HA: ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer. 5:341–354. 2005. View Article : Google Scholar : PubMed/NCBI
4	Olayioye MA, Neve RM, Lane HA and Hynes NE: The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J. 19:3159–3167. 2000. View Article : Google Scholar : PubMed/NCBI
5	Konecny GE, Pegram MD, Venkatesan N, Finn R, Yang G, Rahmeh M, Untch M, Rusnak DW, Spehar G, Mullin RJ, et al: Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res. 66:1630–1639. 2006. View Article : Google Scholar : PubMed/NCBI
6	Smith BL, Chin D, Maltzman W, Crosby K, Hortobagyi GV and Bacus SS: The efficacy of Herceptin therapies is influenced by the expression of other erbB receptors, their ligands and the activation of downstream signalling proteins. Br J Cancer. 91:1190–1194. 2004.PubMed/NCBI
7	Sergina NV, Rausch M, Wang D, Blair J, Hann B, Shokat KM and Moasser MM: Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature. 445:437–441. 2007. View Article : Google Scholar : PubMed/NCBI
8	Ray RB, Raychoudhuri A, Steele R and Nerurkar P: Bitter melon (Momordica charantia) extract inhibits breast cancer cell proliferation by modulating cell cycle regulatory genes and promotes apoptosis. Cancer Res. 70:1925–1931. 2010.PubMed/NCBI
9	Grossmann ME, Mizuno NK, Dammen ML, Schuster T, Ray A and Cleary MP: Eleostearic acid inhibits breast cancer proliferation by means of an oxidation-dependent mechanism. Cancer Prev Res (Phila). 2:879–886. 2009. View Article : Google Scholar : PubMed/NCBI
10	Moon HS, Guo DD, Lee HG, Choi YJ, Kang JS, Jo K, Eom JM, Yun CH and Cho CS: Alpha-eleostearic acid suppresses proliferation of MCF-7 breast cancer cells via activation of PPARγ and inhibition of ERK 1/2. Cancer Sci. 101:396–402. 2010.PubMed/NCBI
11	Zhang T, Gao Y, Mao Y, Zhang Q, Lin C, Lin P, Zhang J and Wang X: Growth inhibition and apoptotic effect of alpha-eleostearic acid on human breast cancer cells. J Nat Med. 66:77–84. 2012. View Article : Google Scholar : PubMed/NCBI
12	Dolcet X, Llobet D, Pallares J and Matias-Guiu X: NF-κB in development and progression of human cancer. Virchows Arch. 446:475–482. 2005.
13	Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y and Greenberg ME: Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell. 91:231–241. 1997. View Article : Google Scholar : PubMed/NCBI
14	Dhillon S: Everolimus in combination with exemestane: a review of its use in the treatment of patients with postmenopausal hormone receptor-positive, HER2-negative advanced breast cancer. Drugs. 73:475–485. 2013. View Article : Google Scholar : PubMed/NCBI
15	Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T and Thun MJ: Cancer statistics, 2008. CA Cancer J Clin. 58:71–96. 2008. View Article : Google Scholar
16	Brennan SF, Cantwell MM, Cardwell CR, Velentzis LS and Woodside JV: Dietary patterns and breast cancer risk: a systematic review and meta-analysis. Am J Clin Nutr. 91:1294–1302. 2010. View Article : Google Scholar : PubMed/NCBI
17	Montales MT, Rahal OM, Kang J, Rogers TJ, Prior RL, Wu X and Simmen RC: Repression of mammosphere formation of human breast cancer cells by soy isoflavone genistein and blueberry polyphenolic acids suggests diet-mediated targeting of cancer stem-like/progenitor cells. Carcinogenesis. 33:652–660. 2012. View Article : Google Scholar
18	Tsuzuki T, Tokuyama Y, Igarashi M, Nakagawa K, Ohsaki Y, Komai M and Miyazawa T: α-eleostearic acid (9Z11E13E-18:3) is quickly converted to conjugated linoleic acid (9Z11E-18: ) in rats. J Nutr. 134:2634–2639. 2004.
19	Ru P, Steele R, Nerurkar PV, Phillips N and Ray RB: Bitter melon extract impairs prostate cancer cell-cycle progression and delays prostatic intraepithelial neoplasia in TRAMP model. Cancer Prev Res. 4:2122–2130. 2011. View Article : Google Scholar : PubMed/NCBI
20	Nahta R, Yu D, Hung MC, Hortobagyi GN and Esteva FJ: Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol. 3:269–280. 2006. View Article : Google Scholar : PubMed/NCBI
21	Vaught DB, Stanford JC, Young C, Hicks DJ, Wheeler F, Rinehart C, Sánchez V, Koland J, Muller WJ, Arteaga CL and Cook RS: HER3 is required for HER2-induced preneoplastic changes to the breast epithelium and tumor formation. Cancer Res. 72:2672–2682. 2012. View Article : Google Scholar : PubMed/NCBI
22	Menendez JA, Vazquez-Martin A, Ropero S, Colomer R, Lupu R and Trueta J: HER2 (erbB-2)-targeted effects of the omega-3 polyunsaturated. Fatty acid α-linolenic acid (ALA; 18: 3n−3) in breast cancer cells: the ‘fat features’ of the ‘Mediterranean diet’ as an ‘anti-HER2 cocktail’. Clin Trans Oncol. 8:812–820. 2006.PubMed/NCBI
23	Carracedo A and Pandolfi PP: The PTEN-PI3K pathway: of feedbacks and cross-talks. Oncogene. 27:5527–5541. 2008. View Article : Google Scholar : PubMed/NCBI
24	Eom JM, Seo MJ, Baek JY, Chu H, Han SH, Min TS, Cho CS and Yun CH: Alpha-eleostearic acid induces autophagy-dependent cell death through targeting AKT/mTOR and ERK1/2 signal together with the generation of reactive oxygen species. Biochem Biophys Res Commun. 391:903–908. 2010. View Article : Google Scholar : PubMed/NCBI
25	Draczynska-Lusiak B, Chen YM and Sun AY: Oxidized lipoproteins activate NF-kappaB binding activity and apoptosis in PC12 cells. Neuroreport. 9:527–532. 1998. View Article : Google Scholar : PubMed/NCBI